ALK+ NSCLC: alectinib tops crizotinib in head-to-head trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Treatment with alectinib (Alecensa) resulted in superior PFS compared with crizotinib (Xalkori) in ALK inhibitor-naive patients with ALK-positive NSCLC.
Why this matters
  • These findings could potentially change the standard of care for the first-line treatment of ALK-positive NSCLC.